A Prospective Investigation of Bispecific CD19/22 CAR T Cell Therapy in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

BACKGROUND: The use of T cells expressing chimeric antigen receptor (CAR T) engineered to target CD19 constitutes breakthrough treatment for relapsed or refractory B cell non-Hodgkin lymphoma (R/R B-NHL). Despite improved outcomes, high relapse rate remains a challenge to overcome. Here, we report t...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Ying, Li, Jiaqi, Lou, Xiaoyan, Chen, Xiaochen, Yu, Zhou, Kang, Liqing, Chen, Jia, Zhou, Jin, Zong, Xiangping, Yang, Zhen, Li, Minghao, Xu, Nan, Jia, Sixun, Geng, Hongzhi, Chen, Guanghua, Dai, Haiping, Tang, Xiaowen, Yu, Lei, Wu, Depei, Li, Caixia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8185372/
https://www.ncbi.nlm.nih.gov/pubmed/34113569
http://dx.doi.org/10.3389/fonc.2021.664421

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8185372/
https://www.ncbi.nlm.nih.gov/pubmed/34113569
http://dx.doi.org/10.3389/fonc.2021.664421

Ejemplares similares